Drugs / Restylane® Lyft
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04162002 | Oct → Nov 2019 | — | DeNova Research | Completed | Met primary |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2026-01-22 | Galderma R&D | Results IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio galderma.com ↗
Data from across Galderma’s portfolio of Restylane HA treatments will be presented supporting its versatile use on the face and décolletage, with a range of gel formulations to meet personalized needs from providing structural support to smoothing lines and wrinkles: |
| 2025-11-17 | Galderma R&D | Results ASDS 2025: Compelling new data on Restylane, Sculptra and Relfydess highlight Galderma’s innovative Injectable Aesthetics portfolio and pipeline galderma.com ↗
Nine-month results from a first-of-its-kind clinical trial were presented, reinforcing that the treatment regimen of Restylane Lyft or Restylane Contour with Sculptra® delivers sustained aesthetic facial improvements for patients experiencing facial aesthetic changes after medication-driven weight loss4 |
| 2025-11-05 | Galderma R&D | Regulatory Galderma receives U.S. FDA approval for Restylane® Lyft™ for the enhancement of the chin profile galderma.com ↗ |
| 2025-10-23 | Galderma R&D | Results Galderma delivers record net sales of 3.737 billion USD in the first nine months of 2025 and 15.0% year-on-year growth at constant currency, raises full-year guidance galderma.com ↗
Reinforced scientific leadership in dermatology, presenting new long-term data on Nemluvio, nine-month data on Restylane® and Sculptra® showing sustained results in addressing facial changes from medication-driven weight loss, and continuing investment in market-leading education |
| 2025-09-24 | Galderma R&D | Results AMWC Dubai: Galderma demonstrates Injectable Aesthetics leadership through updates on its scientific innovations and community education galderma.com ↗
Galderma will present findings from the ARTIST post-marketing study showing that The Shayping Technique™ – a holistic treatment approach using three Restylane® injectables – significantly enhances facial features and overall appearance, supporting its use to meet diverse patient needs1 |
| 2025-07-17 | Galderma R&D | Results Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss galderma.com ↗
Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss. |
| 2025-01-14 | Galderma R&D | Results Galderma premieres positive interim results demonstrating the efficacy of its Injectable Aesthetics portfolio in addressing facial volume loss as a result of medication-driven weight loss galderma.com ↗
Three-month interim data from first-of-its-kind trial demonstrate that the combination of Sculptra® and Restylane® Lyft™ or Contour™ effectively improved the facial aesthetic appearance of patients experiencing medication-driven weight loss with associated facial volume loss1 |
| 2022-03-28 | Galderma R&D | Results Galderma to present new clinical data and high patient satisfaction across their portfolio of dermal fillers, collagen biostimulators and liquid neuromodulators at AMWC 2022 galderma.com ↗
Results from Dr Andreas Nikolis’ CHEEKY post-market study evaluated treatment with Restylane® Lyft™ for those needing a projection effect and Restylane® Volyme™ for a contouring/volumizing effect. |
| 2020-04-22 | Galderma R&D | Regulatory Galderma receives approval for Restylane® Vital™, Restylane® Lyft™, and Restylane® Lidocaine in China galderma.com ↗
Galderma announced that it has received three new approvals from the National Medical Products Administration of China, NMPA, with Restylane® Vital™, Restylane® Lidocaine and Restylane® Lyft™ Lidocaine, further expanding the Restylane portfolio in China. |
| 2018-11-05 | Galderma R&D | Regulatory Galderma Announces FDA Approval of Restylane® Lyft For Midface Injection via Cannula galderma.com ↗
Galderma Announces FDA Approval of Restylane® Lyft For Midface Injection via Cannula |
| 2018-05-22 | Galderma R&D | Regulatory FDA Approval of Restylane® Lyft for Hands galderma.com ↗
Nestlé Skin Health, a global leader focused on meeting the world's increasing skin health needs, announced today that the U.S. Food and Drug Administration (FDA) has approved the hyaluronic acid (HA) dermal filler Restylane® Lyft for the correction of age-related volume loss in the back of the hands for patients over the age of 21. |
| 2018-05-21 | Galderma R&D | Regulatory Nestlé Skin Health Announces the FDA Approval of Restylane® Lyft for Hands, the First and Only Hyaluronic Acid (HA) Dermal Filler for Use in the Back of Hands galderma.com ↗
Restylane Lyft is the first and only HA injectable gel to be FDA-approved for restoring fullness to the back of the hands 2,3, providing more youthful-looking skin4. |
All press releases naming this drug 12 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Restylane Lyft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04162002 ↗ |